WuXi Biologics Opens Expanded $150 Million Biomanufacturing Facility

23:56 EST 7 Dec 2017 | ChinaBio Today

WuXi Biologics has completed construction of its $150 million 30,000 liter biomanufacturing facility in China. The CRO/CMO initially announced it would build the facility in April 2015. Completed in two stages, the plant has begun operating fourteen 2,000 liter disposable bioreactors for fed-batch cell culture in the facility, the second construction phase, greatly expanding Phase I capacity, which consisted of two 1000 liter disposable bioreactors. WuXi Biologics' plant, located in Wuxi city offers cGMP contract manufacturing services for biologic drugs to WuXi clients. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

Original Article: WuXi Biologics Opens Expanded $150 Million Biomanufacturing Facility


More From BioPortfolio on "WuXi Biologics Opens Expanded $150 Million Biomanufacturing Facility"

Quick Search


Relevant Topics

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...